Company intelligence / Profile preview

Phoenix Biotechnology

San Antonio, Texas, United States

Ownership: Private
Development stage: Other

Overview

The company is developing natural therapies, particularly oleander-based products like oleandrin, which have shown efficacy against enveloped viruses and potential in cancer treatment. However, some of these products have faced regulatory challenges, such as the FDA rejection of oleandrin as a dietary supplement.

Therapeutic areas: OncologyInfectious DiseasesOtherNeurology
Modalities: Natural productsoleander extracts
Industry: Biotech

Partnerships

Duke UniversityJohns Hopkins Medical CenterU.S. Army

Beyond the preview

Go deeper on Phoenix Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phoenix Biotechnology.

Explore the full profile